Download pdf
Oncolytic Virotherapy's Current and Prospective Applications in the Management of Melanoma
- 1 Sichuan University, Chengdu, China
* Author to whom correspondence should be addressed.
Abstract
Oncolytic viruses (OVs) have emerged as a groundbreaking class of cancer therapeutics, demonstrating remarkable potential in the treatment of melanoma in recent years. By lysing and infecting tumor cells only, these viruses cause systemic antitumor immune responses while avoiding harm to healthy organs. This article provides a systematic review of the clinical applications of OVs in melanoma therapy, based on an analysis of relevant literature from the PubMed database spanning 2021 to 2025. The findings highlight that herpes simplex virus type 1 (HSV-1) and V937 (a modified coxsackievirus) are the most commonly utilized oncolytic viruses due to their proven safety profiles and tumor-targeting efficiency. Granulocyte-macrophage colony-stimulating factor (GM-CSF) serves as the predominant transgene, enhancing immune activation by promoting dendritic cell recruitment and T-cell priming. Melanoma, particularly advanced or metastatic forms that are resistant to conventional therapies, remains the primary target of OV-based treatments. The main routes of administration include intratumoral injection (for localized lesions) and intravenous delivery (for disseminated disease). Notably, combination therapies involving OVs and immune checkpoint inhibitors (such as anti-PD-1/PD-L1 antibodies) have shown synergistic effects, significantly improving response rates and survival outcomes in clinical trials. However, challenges such as variability in clinical responses, the potential for preexisting immunity to limit efficacy, and the need for optimized delivery methods persist. Despite the promising potential of OVs in melanoma treatment, further research is essential to optimize their clinical application.
Keywords
Oncolytic virotherapy, melanoma, immune checkpoint inhibitors, GM-CSF, intratumoral injection
[1]. Huang J, Chan S C, Ko S, et al. Global Incidence, Mortality, Risk Factors and Trends of Melanoma: A Systematic Analysis of Registries. American Journal of Clinical Dermatology, 2023, 24(6): 965-975.
[2]. Long G V, Swetter S M, Menzies A M, et al. Cutaneous melanoma. Lancet, 2023, 402(10400): 485-502.
[3]. Mirzayans R, Murray D. What Are the Reasons for Continuing Failures in Cancer Therapy? Are Misleading/Inappropriate Preclinical Assays to Be Blamed? Might Some Modern Therapies Cause More Harm than Benefit? International Journal of Molecular Sciences, 2022, 23(21): 13217.
[4]. Wang X, Tian H, Chi Z, et al. Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights. Journal for ImmunoTherapy of Cancer, 2025, 13(2): e010662.
[5]. Smith K E R, Peng K W, Pulido J S, et al. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. Frontiers in Immunology, 2023, 14: 1279387.
[6]. Liu J, Wang X, Li Z, et al. Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial. Signal Transduction and Targeted Therapy, 2024, 9(1): 318.
[7]. Chesney J A, Ribas A, Long G V, et al. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. Journal of Clinical Oncology, 2023, 41(3): 528-540.
[8]. Cui C, Wang X, Lian B, et al. OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study. Journal for ImmunoTherapy of Cancer, 2022, 10(4): e004307.
[9]. Ahamadi M, Kast J, Chen P W, et al. Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma. CPT: Pharmacometrics & Systems Pharmacology, 2023, 12(2): 250-260.
[10]. Lutzky J, Sullivan R J, Cohen J V, et al. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. Journal of Cancer Research and Clinical Oncology, 2023, 149(9): 6059-6066.
[11]. Chesney J A, Puzanov I, Collichio F A, et al. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. Journal for ImmunoTherapy of Cancer, 2023, 11(5): e006270.
[12]. Schwarze J K, Tijtgat J, Awada G, et al. Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. Journal for ImmunoTherapy of Cancer, 2022, 10(9): e005141.
[13]. Yamazaki N, Isei T, Kiyohara Y, et al. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. Cancer Science, 2022, 113(8): 2798-2806.
[14]. Dummer R, Gyorki D E, Hyngstrom J, et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nature Medicine, 2021, 27(10): 1789-1796.
[15]. Beasley G M, Nair S K, Farrow N E, et al. Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. Journal for ImmunoTherapy of Cancer, 2021, 9(4): e002203.
[16]. Beasley G M, Brown M C, Farrow N E, et al. Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. Journal for ImmunoTherapy of Cancer, 2022, 10(9): e005052.
[17]. Dummer R, Robert C, Scolyer R A, et al. Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial. Nature Medicine, 2025, 31(1): 144-151.
[18]. Malvehy J, Samoylenko I, Schadendorf D, et al. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. Journal for ImmunoTherapy of Cancer, 2021, 9(3): e001621.
Cite this article
Liu,S. (2025). Oncolytic Virotherapy's Current and Prospective Applications in the Management of Melanoma. Theoretical and Natural Science,113,1-8.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICBioMed 2025 Symposium: AI for Healthcare: Advanced Medical Data Analytics and Smart Rehabilitation
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).